Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Lundbeck and Teva ‘enter 5th-largest EU Parkinson’s disease market’

Lundbeck and Teva ‘enter 5th-largest EU Parkinson’s disease market’

14th January 2010

Lundbeck and Teva have revealed their intentions to penetrate Europe’s fifth-largest pharmaceutical market by releasing the therapy Azilect (rasagiline) in France.

The once-daily tablets are indicated for the treatment of Parkinson’s disease both as initial monotherapy in the condition’s early stages and as adjunct to levodopa in the later stages.

According to the firm, the European market value comprises almost 50 per cent of the global demand for Parkinson’s disease treatments and is estimated at approximately 2.7 billion euros (2.41 billion pounds).

Stig Lokke Pedersen, executive vice-president of commercial operations at Lundbeck, said: “Azilect is the first and only product that has demonstrated effect on slowing clinical progression of Parkinson’s disease and we are looking forward to providing it to the French market.”

Last month, Lundbeck announced the positive results of two clinical trials into its schizophrenia therapy zicronapine.

Both studies indicated that the drug demonstrated noticeable statistical separation from placebo at 7 and 10 mg doses.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.